Clinical Trials Browser

INDUSTRY × pegfilgrastim × Thoracic × Clear all

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT01840579 2021-06-22

MK-3475-011

Phase 1 Completed

57 enrolled 60 charts

Thoracic

Carcinoma, Non-Small-Cell Lung, Small Cell Lung Carcinoma

NCT01059643 2019-09-18

A Study in Ovarian, Non-Small Cell Lung, Prostate, Colorectal, Gastroesophageal Cancers, and Squamous Cell Carcinoma of the Head and Neck

Phase 2 Completed

103 enrolled 14 charts

GastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Head and Neck Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms

NCT02087176 2016-06-14

A Placebo Controlled Study Comparing AZD1775+ Docetaxel Versus Placebo+Docetaxel to Treat Lung Cancer

Phase 2 Terminated

48 enrolled 11 charts

Thoracic

Previously Treated Non Small Cell Lung Cancer

NCT00117442 2013-05-13

A Study of Carboplatin/Paclitaxel With Pegfilgrastim Supported by Haematopoietic Progenitor Cell Re-Infusion in Whole Blood

Phase 2 Completed

61 enrolled

BreastGynecologicThoracic

Breast Neoplasms, Lung Neoplasms, Ovarian Neoplasms

NCT00277160 2010-10-08

A Study of Primary Prophylaxis With Neulasta (Pegfilgrastim) Versus Secondary Prophylaxis After Chemotherapy in Elderly Subjects (>/= 65 Years Old) With Cancer

Phase 4 Completed

852 enrolled

BreastGynecologicLymphoidThoracic

Breast Neoplasms, Lung Neoplasms, Lymphoma, Non-Hodgkin, Neutropenia, Ovarian Neoplasms

NCT00115206 2009-04-06

Neulasta® in Subjects With Advanced Non-Small-Cell Lung Cancer (NSCLC) During Chemotherapy

Phase 4 Completed

Thoracic

Carcinoma, Non-Small-Cell Lung, Fever, Neutropenia

Clinical Trials

SELECT-1

MK-3475-011

A Study in Ovarian, Non-Small Cell Lung, Prostate, Colorectal, Gastroesophageal Cancers, and Squamous Cell Carcinoma of the Head and Neck

A Placebo Controlled Study Comparing AZD1775+ Docetaxel Versus Placebo+Docetaxel to Treat Lung Cancer

A Study of Carboplatin/Paclitaxel With Pegfilgrastim Supported by Haematopoietic Progenitor Cell Re-Infusion in Whole Blood

A Study of Primary Prophylaxis With Neulasta (Pegfilgrastim) Versus Secondary Prophylaxis After Chemotherapy in Elderly Subjects (>/= 65 Years Old) With Cancer

Neulasta® in Subjects With Advanced Non-Small-Cell Lung Cancer (NSCLC) During Chemotherapy